| SC 13D/A | 2024-04-16 | Rubric Capital Management LP | Mereo BioPharma Group plc | 99,714,985 | 14.2% | EDGAR |
| SC 13G/A | 2024-02-14 | ORBIMED ADVISORS LLC | Mereo BioPharma Group plc | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | Rock Springs Capital Management LP | Mereo BioPharma Group plc | 39,919,255 | 6.4% | EDGAR |
| SC 13G/A | 2024-02-14 | Rock Springs Capital Management LP | Mereo BioPharma Group plc | 39,919,255 | 5.7% | EDGAR |
| SC 13G | 2024-02-14 | MANGROVE PARTNERS IM, LLC | Mereo BioPharma Group plc | 43,764,465 | 6.2% | EDGAR |
| SC 13G/A | 2024-02-13 | SUVRETTA CAPITAL MANAGEMENT, LLC | Mereo BioPharma Group plc | 36,854,190 | 5.3% | EDGAR |
| SC 13G/A | 2024-02-06 | Soleus Private Equity Fund III, L.P. | Mereo BioPharma Group plc | 18,145,160 | 2.6% | EDGAR |
| SC 13G | 2024-02-05 | ADAGE CAPITAL PARTNERS GP, L.L.C. | Mereo BioPharma Group plc | 50,250,000 | 7.2% | EDGAR |
| SC 13D/A | 2023-11-20 | Rubric Capital Management LP | Mereo Biopharma Group plc | 99,704,885 | 14.2% | EDGAR |
| SC 13D/A | 2023-11-15 | Rubric Capital Management LP | Mereo Biopharma Group plc | 97,326,555 | 13.9% | EDGAR |
| SC 13D/A | 2023-11-13 | Rubric Capital Management LP | Mereo Biopharma Group plc | 97,319,355 | 13.9% | EDGAR |
| SC 13D/A | 2023-11-08 | Rubric Capital Management LP | Mereo Biopharma Group plc | 95,561,160 | 13.6% | EDGAR |
| SC 13D/A | 2023-11-06 | Rubric Capital Management LP | Mereo Biopharma Group plc | 93,372,585 | 13.3% | EDGAR |
| SC 13D/A | 2023-11-02 | Rubric Capital Management LP | Mereo Biopharma Group plc | 92,291,205 | 13.2% | EDGAR |
| SC 13D/A | 2023-10-31 | Rubric Capital Management LP | Mereo Biopharma Group plc | 92,199,075 | 13.2% | EDGAR |
| SC 13G/A | 2023-08-10 | BAKER BROS. ADVISORS LP | Mereo Biopharma Group plc | 14,604,391 | 2.2% | EDGAR |
| SC 13G | 2023-07-26 | Soleus Private Equity Fund III, L.P. | Mereo Biopharma Group plc | 18,145,160 | 2.8% | EDGAR |
| SC 13D/A | 2023-06-16 | Rubric Capital Management LP | Mereo Biopharma Group plc | 90,030,600 | 14.4% | EDGAR |
| SC 13G/A | 2023-02-14 | Point72 Asset Management, L.P. | Mereo Biopharma Group plc | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-14 | ORBIMED ADVISORS LLC | Mereo Biopharma Group plc | 8,302,904 | 4.7% | EDGAR |